Tag: Immunotherapy

B7-H4 (also known as B7 homolog 4, B7S1, or VTCN1) is an immunoregulatory ligand in the B7-CD28 family, notable for its overexpression in multiple tumor types, including breast, ovarian, uterine, and lung cancers. B7-H4 suppresses T-cell effector functions, including inflammatory cytokine production and cytolytic activity, and promotes the polarisation of naïve CD4 T-cells into induced Tregs, invasion, and metastasis, correlating with poor prognosis in advanced tumors. Its restricted expression in normal tissues and tumor-promoting roles make B7-H4 an attractive target for tumor-selective therapies such as antibody-drug conjugates (ADCs). B7-H4 has attracted credible attention from drug developers because it is highly expressed in immune 'cold' tumors, in which PD-1 and PD-L1 are minimally expressed, making these tumors unresponsive to most currently used immunotherapies.

Inotuzumab ozogamicin (Besponsa®; Pfizer), a humanized anti-CD22 antibody-drug conjugate that has shown significant activity in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) as demonstrated in the phase 3 INO-VATE trial *(NCT01564784), [1], has demonstrated encouraging remission rates as salvage therapy for patients with R/R B-ALL, with overall survival of 51.7% (SD 8.1%) and event-free survival of 32.4% (SD 8.0%).

Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).

The US Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications from Cambridge, Massachusetts-based biotech Pyxis Oncology, allowing the company to...

CD47, an immunoglobulin also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on the surface of normal, healthy, hematopoietic stem cells (HSC)...

Immunomedics and Roche have agreed to expand their clinical trial collaboration to evaluate sacituzumab govitecan-hziy (Trodelvy™), a Trop-2-directed antibody conjugated to a topoisomerase I...

Connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab | Yervoy®; Bristol-Myers Squibb Company) and anti-PD-L1 (atezolizumab | Tecentriq®; Genentech) to peptides that...

In late January, ECCO2017: European Cancer Congress will be held in Amsterdam, The Netherlands. The organizers promote the meeting as the only truly multidisciplinary...

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

Baeuerle and Raum present an extensive review of BsAbs in their article. [2] BsAbs are most commonly used for cancer immunotherapy where they are targeted to simultaneously bind to a cytotoxic cell as well as a target tumor cell to be destroyed. Targeting two antigens simultaneously can be a promising approach. This paper will include a review of the challenges associated with the manufacturing of BsAbs in mammalian cell cultures, and the strategies that can be implemented to overcome treatment challenges.